Compound 1400
Identifiers
- Canonical SMILES:
FC(F)(F)c1cc(ccc1Sc1ccccc1N1CCOCC1)[C@@H]1C[C@H]1C(=O)NCCCN1CCCC1=O
- IUPAC name:
2-[4-(2-morpholin-4-ylphenyl)sulfanyl-3-(trifluoromethyl)phenyl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]cyclopropane-1-carboxamide
- InChi:
InChI=1S/C28H32F3N3O3S/c29-28(30,31)22-17-19(20-18-21(20)27(36)32-10-4-12-34-11-3-7-26(34)35)8-9-24(22)38-25-6-2-1-5-23(25)33-13-15-37-16-14-33/h1-2,5-6,8-9,17,20-21H,3-4,7,10-16,18H2,(H,32,36)/t20-,21+/m0/s1
- InChiKey:
WZWKDGGJAXYHLC-LEWJYISDSA-N
External links
![]() 168317976 |
![]() 19174432 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
0 | 1 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
LFA / ICAM | 7.82 | immune system disease | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 547.21 g/mol | |||
HBA | 6 | |||
HBD | 1 | |||
HBA + HBD | 7 | |||
AlogP | 3.88 | |||
TPSA | 61.88 | |||
RB | 10 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 0 | 1 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5000 | Carphenazine | DB01038 | |
0.4969 | Butaperazine | DB13213 | |
0.4808 | Periciazine | DB01608 | |
0.4774 | Fluphenazine | DB00623 | |
0.4740 | Propiopromazine | DB11540 | |
0.4720 | Acetophenazine | DB01063 | |
0.4690 | Doxapram | DB00561 | |
0.4578 | Emodepside | DB11403 | |
0.4564 | R-30490 | DB09179 | |
0.4520 | Etymemazine | DB11517 | |
0.4520 | Benazepril | DB00542 | |
0.4507 | Mequitazine | DB01071 | |
0.4494 | Lofentanil | DB09174 | |
0.4494 | Carfentanil, C-11 | DB15360 | |
0.4494 | Carfentanil | DB01535 |